The SYNERGY II Everolimus elutiNg stent In patients Older than 75 years undergoing coronary Revascularisation associated with a short dual antiplatelet therapy (SENIOR) trial: rationale and design of a large-scale randomised multicentre study

Olivier Varenne1,2*, MD, PhD; Thomas Cuisset3, MD, PhD; Aurès Chaïb1,2, MD; Marie-Claude Morice4, MD; Manel Sabaté5, MD; Tian-Hai Koh6, MD; Isabelle Durand-Zaleski7, MD, PhD; Olivier Hanon2,8, MD, PhD; Kris Bogaerts9,10, PhD; Peter Sinnaeve11, MD, PhD

1. AP-HP, Hôpital Cochin, Service de Cardiologie, Paris, France; 2. Université Paris Descartes, Université Sorbonne Paris Cité, Paris, France; 3. AP-HM, Hôpital de la Timone, Service de Cardiologie, Marseille, France; 4. Générale de Santé, Institut Cardio

Aims: In the elderly population, bare metal stents (BMS) are often preferred over drug-eluting stents (DES) because of the longer duration of dual antiplatelet therapy (DAPT) associated w

Sign in to read and download the full article

Login Forgot your password?

No account yet? Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

bare metal stentcoronary artery diseaseclinical research

Coronary interventionsStents and scaffoldsAdjunctive pharmacotherapy

Share on Facebook Share on Twitter Share on Linkedin

Read next article

Angiographic outcomes of Orsiro biodegradable polymer sirolimus-eluting stents and Resolute Integrity durable polymer zotarolimus-eluting stents: results of the ORIENT trial